Rheumatology Doctors in Granger, IN Accepting Medicare

3 Rheumatology doctors found. Showing 1 - 3

Dr. Mary Ann R Domingo, M.D. Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 6901 N Main St Ste 102, Granger, IN 46530 Phone: 574-647-4500    Fax: 574-647-6354

Dr. Nicholas Ralph Straniero, M.D. Internal Medicine - Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 6913 N Main St, Granger, IN 46530 Phone: 574-647-1500    Fax: 574-243-4310

Dr. Natali M Balog, MD Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 6901 N Main St Ste 102, Granger, IN 46530 Phone: 574-647-4500    Fax: 574-647-6354

News Archive

Low-intensity case management cuts chronic obstructive pulmonary disease-related hospital visits in half

A new study has found that patients with chronic obstructive pulmonary disease (COPD) who are at high risk for hospitalization or emergency room visits from exacerbations or complications benefit from simple low-intensity case management.

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Geron Corporation announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron's Investigational New Drug (IND) application has been lifted and the company's Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed.

FDA provides positive review of InNexus' lead preclinical drug candidate

InNexus Biotechnology Inc. has announced the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).

Understanding the changing coronavirus landscape

With the emergence of new SARS-CoV-2 variants such as beta and delta, people are not only getting a refresher course on the Greek alphabet but also experiencing confusion and anxiety about what the variants mean for public health.

NCCN Guidelines adds ofatumumab and romidepsin as therapy options for CLL

Two recent FDA approvals have prompted the National Comprehensive Cancer Network (NCCN) to update the NCCN Clinical Practice Guidelines in Oncology(TM) for Non-Hodgkin's Lymphomas to include ofatumumab (Azerra(TM), GlaxoSmithKline) and romidepsin (Istodax(R), Gloucester Pharmaceuticals) as treatment options for select patients with two types of Non-Hodgkin's Lymphomas.

Read more Medical News

› Verified 8 days ago